DDInter1642 DDInter1847
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.
Trastuzumab deruxtecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sipuleucel-T
Trastuzumab deruxtecan {u} may lead to a major life threatening interaction when taken with {v} Samarium (153Sm) lexidronam
Trastuzumab deruxtecan {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Trastuzumab deruxtecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Trastuzumab deruxtecan may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Trastuzumab deruxtecan may lead to a major life threatening interaction when taken with Upadacitinib